Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Mitochondrial approaches for neuroprotection.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Glatiramer acetate does not protect from acute ischemic stroke in mice.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
White matter astrocytes in health and disease.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Remyelination therapy goes to trial for multiple sclerosis
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Pages